Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
121,543,157
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
14,115,568
-
Shares change
-
-50,664
-
Total reported value, excl. options
-
$63,519,000
-
Value change
-
-$267,929
-
Number of buys
-
6
-
Number of sells
-
-7
-
Price
-
$4.50
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q3 2019
20 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2019.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14,115,568 shares
of 121,543,157 outstanding shares and own 12% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (6,324,319 shares), NEA Management Company, LLC (4,441,360 shares), Omega Fund Management, LLC (1,263,408 shares), FMR LLC (792,700 shares), FRANKLIN RESOURCES INC (700,000 shares), Schonfeld Strategic Advisors LLC (168,810 shares), VANGUARD GROUP INC (150,432 shares), DRIEHAUS CAPITAL MANAGEMENT LLC (125,000 shares), Alyeska Investment Group, L.P. (60,535 shares), and GEODE CAPITAL MANAGEMENT, LLC (41,482 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.